Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2024

Genmab — Januar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Pensionisten
    wrote on sidst redigeret af
    #1106

    Vi kan jo håbe lidt på, at Jan nu kan lukke lidt mere op for posen - nu er voldgiftsbåndet væk.Må indrømme, at jeg håber lidt på, at kvartalsregnskabet følges op med en lidt håndfast strategi.

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #1107

      Synes Jan sagde på ASH eller JP Morgan, at de i højere grad retter fokus mod development og holder lidt igen på research. Sikkert klogt med patentudløb på daratumumab for øje. Drømmer stadig om at GEN1042 kan noget særligt, men blev lidt nervøs da vi intet hørte i slutningen af 2023.

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #1108

        Må vist lige finde den præcise formulering i weekenden.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #1109

          NJ Stock: What to Consider Before Its Next Dividend Hike https://www.proinvestor.com/investornyt/1108802/jnj-stock-what-to-consider-before-its-next-dividend-hike

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #1110

            Perseus video https://www.youtube.com/watch?v=mpiSaMj0kFY

            1 Reply Last reply
            0
            • W Offline
              W Offline
              w
              wrote on sidst redigeret af
              #1111

              ØU https://ugebrev.dk/flashnews/teknisk-var-det-bunden-for-genmab-efter-en-lang-nedtur/

              1 Reply Last reply
              0
              • H Offline
                H Offline
                Hen
                wrote on sidst redigeret af
                #1112

                Låst artikel.
                "Vi har senest øget positionen i Genmab i ØUs portefølje, da der med de seneste meddelelser er taget en del risiko ud af aktien." Hvilke meddelelser er det, de sigter til?

                1 Reply Last reply
                0
                • H Offline
                  H Offline
                  Hen
                  wrote on sidst redigeret af
                  #1113

                  Slet ingen med adgang til AU?

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #1114

                    I have not read the article, but i assume he means that there is no more uncertainty about the arbitrage -the (negative) outcome is now known, so that particular risk is now gone

                    1 Reply Last reply
                    0
                    • H Offline
                      H Offline
                      Hen
                      wrote on sidst redigeret af
                      #1115

                      Tak for svaret, EL.

                      1 Reply Last reply
                      0
                      • DarvinD Offline
                        DarvinD Offline
                        Darvin
                        wrote on sidst redigeret af
                        #1116

                        Godmorgen og enig JV 26.01 16.52

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1117

                          All About TALVEY (talquetamab) - video https://www.youtube.com/watch?v=sUQnK-a4TvY

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #1118

                            'epcoritamabe' was also in approved in Brazil last dec
                            https://jornaldr1.com.br/anvisa-aprova-primeiro-anticorpo-biespecifico-para-tratar-tipo-agressivo-de-cancer-no-sangue/

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #1119

                              Alligator Bio har succes med deres CD40 monoclonale antistof Mitazalimab, så lad os håbe Genmab kan toppe den:

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #1120

                                Link Preview Image
                                Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer – Alligator Bioscience

                                Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...

                                favicon

                                (alligatorbioscience.se)

                                1 Reply Last reply
                                0
                                • nohopeN Offline
                                  nohopeN Offline
                                  nohope
                                  wrote on sidst redigeret af
                                  #1121

                                  Skal kun stige yderligere 120 % for at jeg går i nul...

                                  1 Reply Last reply
                                  0
                                  • nohopeN Offline
                                    nohopeN Offline
                                    nohope
                                    wrote on sidst redigeret af
                                    #1122

                                    -Efter den er steget 280 % på 3 mdr...

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #1123

                                      Genmab price target raised by $1 at H.C. Wainwright to$50, maintains buy

                                      1 Reply Last reply
                                      0
                                      • W Offline
                                        W Offline
                                        w
                                        wrote on sidst redigeret af
                                        #1124

                                        insane

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #1125

                                          too low...? 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper